HOOKIPA Pharma Inc.
Jan Micksch is a seasoned professional in the field of quality control and analytical management, currently serving as Senior Manager Quality Control at HOOKIPA Pharma Inc. since March 2023. Previously, Jan held the position of Analytical Manager at Themis Bioscience GmbH and was responsible for various analytical projects as an Analytical Product Owner at Shire. Jan's extensive experience includes leadership roles in process science and analytics, method development, regulatory submissions, and project management across notable organizations such as Baxalta, Baxter International Inc., Boehringer Ingelheim, and Bayer. Jan holds a Master of Science in Engineering with a focus on project and process management from FH Technikum Wien and has a background as a Chemical Laboratory Technician.
This person is not in any offices
HOOKIPA Pharma Inc.
At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.